Literature DB >> 33914858

Neuronal deletion of Wwox, associated with WOREE syndrome, causes epilepsy and myelin defects.

Srinivasarao Repudi1, Daniel J Steinberg1, Nimrod Elazar2, Vanessa L Breton3, Mark S Aquilino3, Afifa Saleem3, Sara Abu-Swai1, Anna Vainshtein2, Yael Eshed-Eisenbach2, Bharath Vijayaragavan2, Oded Behar4, Jacob J Hanna5, Elior Peles2, Peter L Carlen3, Rami I Aqeilan1.   

Abstract

WWOX-related epileptic encephalopathy (WOREE) syndrome caused by human germline bi-allelic mutations in WWOX is a neurodevelopmental disorder characterized by intractable epilepsy, severe developmental delay, ataxia and premature death at the age of 2-4 years. The underlying mechanisms of WWOX actions are poorly understood. In the current study, we show that specific neuronal deletion of murine Wwox produces phenotypes typical of the Wwox-null mutation leading to brain hyperexcitability, intractable epilepsy, ataxia and postnatal lethality. A significant decrease in transcript levels of genes involved in myelination was observed in mouse cortex and hippocampus. Wwox-mutant mice exhibited reduced maturation of oligodendrocytes, reduced myelinated axons and impaired axonal conductivity. Brain hyperexcitability and hypomyelination were also revealed in human brain organoids with a WWOX deletion. These findings provide cellular and molecular evidence for myelination defects and hyperexcitability in the WOREE syndrome linked to neuronal function of WWOX.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  WOREE syndrome; brain organoids; electrophysiology; hypomyelination; seizures

Mesh:

Substances:

Year:  2021        PMID: 33914858     DOI: 10.1093/brain/awab174

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  7 in total

Review 1.  WWOX and metabolic regulation in normal and pathological conditions.

Authors:  Izabela Baryła; Katarzyna Kośla; Andrzej K Bednarek
Journal:  J Mol Med (Berl)       Date:  2022-10-22       Impact factor: 5.606

2.  Novel Mutation With Literature Review WW Domain-Containing Oxidoreductase (WWOX) Gene.

Authors:  Ghassan Sukkar; Razan M Alzahrani; Bsaim A Altirkistani; Rayan S Al Lohaibi
Journal:  Cureus       Date:  2022-05-14

3.  Neonatal neuronal WWOX gene therapy rescues Wwox null phenotypes.

Authors:  Srinivasarao Repudi; Irina Kustanovich; Sara Abu-Swai; Shani Stern; Rami I Aqeilan
Journal:  EMBO Mol Med       Date:  2021-11-07       Impact factor: 12.137

4.  Altered neocortical oscillations and cellular excitability in an in vitro Wwox knockout mouse model of epileptic encephalopathy.

Authors:  Vanessa L Breton; Mark S Aquilino; Srinivasarao Repudi; Afifa Saleem; Shanthini Mylvaganam; Sara Abu-Swai; Berj L Bardakjian; Rami I Aqeilan; Peter L Carlen
Journal:  Neurobiol Dis       Date:  2021-10-09       Impact factor: 5.996

Review 5.  WWOX-Related Neurodevelopmental Disorders: Models and Future Perspectives.

Authors:  Daniel J Steinberg; Rami I Aqeilan
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

6.  A Phenotypic-Driven Approach for the Diagnosis of WOREE Syndrome.

Authors:  Antonella Riva; Giulia Nobile; Thea Giacomini; Marzia Ognibene; Marcello Scala; Ganna Balagura; Francesca Madia; Andrea Accogli; Ferruccio Romano; Domenico Tortora; Mariasavina Severino; Paolo Scudieri; Simona Baldassari; Ilaria Musante; Paolo Uva; Vincenzo Salpietro; Annalaura Torella; Vincenzo Nigro; Valeria Capra; Lino Nobili; Pasquale Striano; Maria Margherita Mancardi; Federico Zara; Michele Iacomino
Journal:  Front Pediatr       Date:  2022-04-29       Impact factor: 3.418

Review 7.  WWOX Controls Cell Survival, Immune Response and Disease Progression by pY33 to pS14 Transition to Alternate Signaling Partners.

Authors:  Tsung-Yun Liu; Ganesan Nagarajan; Ming-Fu Chiang; Shenq-Shyang Huang; Tzu-Chia Lin; Yu-An Chen; Chun-I Sze; Nan-Shan Chang
Journal:  Cells       Date:  2022-07-07       Impact factor: 7.666

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.